Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Jingjun HuangYongjian GuoWensou HuangXiaotao HongYi QuanLiteng LinJingwen ZhouLicong LiangYaqin ZhangJuan ZhouMingyue CaiKang-Shun Zhu

Published in: Journal of hepatocellular carcinoma (2022)

Rego-sintilimab was tolerated and led to better OS than regorafenib as a second-line treatment for advanced HCC patients, especially in those with NLR ≤ 3.6.

Keyphrases

end stage renal disease
metastatic colorectal cancer
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
clinical trial
replacement therapy
patient reported